COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)

ESMO Open

article

L. Castelo-Branco¹  Z. Tsourti³  S. Gennatas⁴  J. Rogado⁵  M. Sekacheva⁶  D. Viñal⁷  R. Lee⁸  A. Croitoru^1,10  M. Vitorino^1,11  S. Khallaf^1,12  S. Šušnjar^1,13  W. Soewoto^1,14  A. Cardeña^1,15  M. Djerouni^1,16  M. Rossi^1,17  T. Alonso-Gordoa^1,18  C. Ngelangel^1,19  J.G. Whisenant^2,20  T.K. Choueiri^2,21  G. Dimopoulou³  S. Pradervand^2,23  D. Arnold^2,24  K. Harrington^2,25  O. Michielin^2,23  U. Dafni^2,26  G. Pentheroudakis¹  S. Peters^2,27  E. Romano^2,28 

[1] Scientific and Medical Division, ESMO ,(European Society for Medical Oncology);NOVA National School of Public Health, NOVA University;Frontier Science Foundation-Hellas;Medical Oncology Department, The Royal Marsden Hospital – NHS Foundation Trust;Medical Oncology Department, Hospital Universitario Infanta Leonor;World-Class Research Center ‘Digital Biodesign and Personalized Healthcare’, Sechenov First Moscow State Medical University;Medical Oncology Department, Hospital Universitario La Paz;Medical Oncology Department, The University of Manchester;The Christie NHS Foundation Trust;Medical Oncology Department, Fundeni Clinical Institute;Servico Oncologia, Hospital Prof. Dr Fernando Fonseca EPE ,(Hospital Amadora/Sintra);Medical Oncology Department, South Egypt Cancer Institute ,(SECI), Assiut University;Department of Medical Oncology, Institute for Oncology and Radiology of Serbia;Department of Surgery, Oncology Division, Sebelas Maret University;Medical Oncology Department, Hospital Universitario Fundación Alcorcón;Oncology Department, Dr Saadane Hospital;Oncology Deparment;Medical Oncology Department, Hospital Universitario Ramón y Cajal;Asian Cancer Institute – Asian Hospital and Medical Center;Vanderbilt University Medical Center;The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute;Harvard Medical School;Oncology Department, Centre Hospitalier Universitaire Vaudois;Oncology, Haematology, Palliative Care Department;Division of Radiotherapy and Imaging, The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre;Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens Frontier Science Foundation-Hellas;Department, Centre Hospitalier Universitaire Vaudois;Center for Cancer Immunotherapy, Department of Oncology, PSL Research University, Institut Curie

关键词: COVID-19;    SARS-CoV-2;    oncology;    cancer;   

DOI  :  10.1016/j.esmoop.2022.100499

学科分类：社会科学、人文和艺术（综合）

来源: BMJ Publishing Group

【 摘 要 】

Background ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management and outcomes of patients with cancer infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).Patients and methods ESMO-CoCARE captures information on patients with solid/haematological malignancies, diagnosed with coronavirus disease 2019 (COVID-19). Data collected since June 2020 include demographics, comorbidities, laboratory measurements, cancer characteristics, COVID-19 clinical features, management and outcome. Parameters influencing COVID-19 severity/recovery were investigated as well as factors associated with overall survival (OS) upon SARS-CoV-2 infection.Results This analysis includes 1626 patients from 20 countries (87% from 24 European, 7% from 5 North African, 6% from 8 Asian/Oceanian centres), with COVID-19 diagnosis from January 2020 to May 2021. Median age was 64 years, with 52% of female, 57% of cancer stage III/IV and 65% receiving active cancer treatment. Nearly 64% patients required hospitalization due to COVID-19 diagnosis, with 11% receiving intensive care. In multivariable analysis, male sex, older age, Eastern Cooperative Oncology Group (ECOG) performance status ≥2, body mass index (BMI) <25 kg/m2, presence of comorbidities, symptomatic disease, as well as haematological malignancies, active/progressive cancer, neutrophil-to-lymphocyte ratio (NLR) ≥6 and OnCovid Inflammatory Score ≤40 were associated with COVID-19 severity (i.e. severe/moderate disease requiring hospitalization). About 98% of patients with mild COVID-19 recovered, as opposed to 71% with severe/moderate disease. Advanced cancer stage was an additional adverse prognostic factor for recovery. At data cut-off, and with median follow-up of 3 months, the COVID-19-related death rate was 24.5% (297/1212), with 380 deaths recorded in total. Almost all factors associated with COVID-19 severity, except for BMI and NLR, were also predictive of inferior OS, along with smoking and non-Asian ethnicity.Conclusions Selected patient and cancer characteristics related to sex, ethnicity, poor fitness, comorbidities, inflammation and active malignancy predict for severe/moderate disease and adverse outcomes from COVID-19 in patients with cancer.

【 授权许可】

CC BY|CC BY-NC-ND